Analysts Offer Predictions for TSE:MDP Q1 Earnings

Key Points

• Raymond James Financial expects Medexus Pharmaceuticals to earn $0.15 per share in Q1 2027, slightly below the current full-year earnings estimate of $0.16 per share.
• Alliance Global Partners upgraded Medexus Pharmaceuticals to a "strong-buy" rating, contributing to an average stock rating of "Buy" with a consensus price target of C$5.49.
• As of the latest trading session, Medexus shares reached C$2.82, with a market capitalization of C$63.13 million and a twelve-month price range between C$1.71 and C$5.56.

Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Raymond James Financial issued their Q1 2027 earnings estimates for shares of Medexus Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 13th. Raymond James Financial analyst M. Freeman expects that the company will earn $0.15 per share for the quarter. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share.

Separately, Alliance Global Partners raised shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research note on Monday. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of C$5.49.

Medexus Pharmaceuticals Price Performance

Shares of MDP stock traded up C$0.07 during trading hours on Friday, reaching C$2.82. The stock had a trading volume of 15,160 shares, compared to its average volume of 73,104. Medexus Pharmaceuticals has a twelve month low of C$1.71 and a twelve month high of C$5.56. The firm has a 50-day simple moving average of C$2.92 and a 200-day simple moving average of C$2.82. The firm has a market capitalization of C$63.13 million, a PE ratio of 13.49 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.